Genedata provides fully integrated enterprise workflow platform to connect data generation, processing, and sharing across R&D sites at Ferring
August 17, 2021
Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Ferring Pharmaceuticals has adopted Genedata Bioprocess® to support end-to-end protein and antibody development processes in their newly formed Biologics Technologies and Development R&D units. With a focus on key therapeutic areas of reproductive medicine & maternal health, gastroenterology, and onco-urology, Ferring will use the Genedata platform to accelerate development of novel peptide-based drugs and biotechnology-derived medicines, such as recombinant proteins and other biologicals. Genedata will provide a fully integrated enterprise workflow platform to connect data generation, processing, and sharing across Ferring R&D sites.
“As part of our growth strategy in innovative biopharmaceuticals, we needed a central platform to capture and process data across our global R&D teams, while ensuring full data integrity and traceability, and Genedata was the only solution that ticked all the boxes right from the start,” said Bjoern Hock, Ph.D., VP Biologics Technologies and Development at Ferring Pharmaceuticals. “Without having to embark on a lengthy and costly customization project, Ferring was able to take advantage of Genedata’s off-the-shelf platform and immediately start using the software across all our R&D sites. The Genedata platform also supports our quality and compliance requirements, functionality completely missing in the other solutions we looked at,” continued Hock.
Since 2018, Ferring pharmaceuticals has embarked on strategic investments in biotherapeutic R&D, highlighted by their new state-of-the-art innovation center in Lausanne, Switzerland. The Genedata platform has been chosen as part of Ferring’s digitalization strategy to ensure full traceability throughout their global organization across process development workflows, including cell line development, cell banking, upstream process development (USP), downstream process development (DSP), formulation development (FD), analytical development (AD), laboratory management, and screening assays. These combined investments underscore Ferring’s strategy to strengthen capabilities and expertise in new biologic agents, such as recombinant proteins and monoclonal antibodies, as it continues to grow.
“We are very pleased that Ferring has chosen Genedata as their digitalization partner to support their rapidly expanding biotherapeutic drug development operations,” said Othmar Pfannes, Ph.D., CEO of Genedata. “Bioprocess development comes with specific functional as well as regulatory and compliance requirements, and we are committed to further invest into our Biopharma Platform to address future development and CMC requirements that enable our customers to bring better biopharmaceuticals more quickly to the market.”